Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients

Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamroz-Wiśniewska, Anna, Zajdel, Radosław, Słowik, Agnieszka, Marona, Monika, Wnuk, Marcin, Adamczyk-Sowa, Monika, Adamczyk, Bożena, Lasek-Bal, Anetta, Puz, Przemysław, Stęposz, Arkadiusz, Krzystanek, Ewa, Patalong-Ogiewa, Maja, Pokryszko-Dragan, Anna, Budrewicz, Sławomir, Koziarska, Dorota, Karbicka, Anna, Wawrzyniak, Sławomir, Fryze, Waldemar, Furtak-Niczyporuk, Marzena, Rejdak, Konrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122749/
https://www.ncbi.nlm.nih.gov/pubmed/33922368
http://dx.doi.org/10.3390/jcm10091830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122749/
https://www.ncbi.nlm.nih.gov/pubmed/33922368
http://dx.doi.org/10.3390/jcm10091830

Ejemplares similares